Wells Fargo Issues a Buy Rating on BioNTech SE (BNTX)
In a report released today, Mohit Bansal from Wells Fargo assigned a Buy rating to BioNTech SE, with a price target of $150.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Eli Lilly & Co. According to TipRanks, Bansal has an average return of 9.2% and a 55.65% success rate on recommended stocks.
In addition to Wells Fargo, BioNTech SE also received a Buy from H.C. Wainwright’s Robert Burns in a report issued on March 31. However, today, TipRanks – DeepSeek reiterated a Hold rating on BioNTech SE (NASDAQ: BNTX).
Based on BioNTech SE’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $898.89 million and a GAAP net loss of $302.14 million. In comparison, last year the company earned a revenue of $1.19 billion and had a net profit of $259.5 million
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.
Read More on BNTX:
Disclaimer & DisclosureReport an Issue
- BioNTech price target lowered to $130 from $140 at H.C. Wainwright
- BioNTech’s Mpox Vaccine Study Reaches Completion: What Investors Should Watch Next
- BioNTech Showcases Late-Stage Lung Cancer Portfolio at ELCC 2026 With Promising Clinical Data
- District court rules federal limits to vaccines not based on science, NYT says
- BioNTech price target lowered to $94 from $116 at TD Cowen
